Companion Diagnostics Oncology Companies

Disclaimer: List of key companies in no particular orderLatest Companion diagnostics Companies Update

• 
  July 2023: Gencurix Inc., a South Korean corporation focusing in molecular diagnostics for cancer, said in July 2023 that it will be participating in the US President's cancer eradication project, "Cancer Moonshot." The Cancer Moonshot is a program of the Biden administration designed to cut the cancer mortality rate in half during the next 25 years. An annual budget of $1.8 billion is allocated to the research and development of novel cancer drugs and diagnostic equipment. As the first domestic cancer molecular diagnostics firm, Gencurix is joining CancerX as well. The business was selected to participate in the Cancer Moonshot program because of the significance of its companion diagnostics technology to the development of targeted cancer therapies.

• 
  October 2023: A new master partnership deal between QIAGEN and Myriad Genetics to create cancer companion diagnostic assays was announced in October 2023. Through this collaboration, pharmaceutical firms will have access to cutting-edge services and products, such as the ability to distribute companion diagnostic test kits to customers throughout the world and the means to develop and commercialize exclusive cancer tests for the clinical market in the United States. Sample preparation, its polymerase chain reaction (PCR), digital PCR (using the QIAcuity system), QIAseq next-generation sequencing (NGS) technology, equipment, and the QIAGEN Digital Insights portfolio of bioinformatics are all part of QIAGEN's Sample to Insight products. Together, the firms' extensive knowledge of FDA and international regulations will ensure that clinical and companion diagnostic applications are fully compliant and integrated.

• Agilent Technologies Inc.


• Illumina, Inc.


• F. Hoffmann-La Roche Ltd


• BioMérieux SA


• Foundation Medicine


• Archer Dx


• Qiagen


• Thermo Fisher Scientific Inc.


• Amoy Dx


• Abbott